Literature DB >> 9244410

How much benefit can be expected from matching for minor antigens in allogeneic marrow transplantation?

P J Martin1.   

Abstract

The presence of recipient disparity for a minor histocompatibility antigen termed HA-1 is associated with an increased risk of grades II-IV GVHD after marrow transplantation from an HLA-identical sibling. These data offer an opportunity to test the validity of theoretical models suggesting that the minor antigens capable of eliciting GVHD in any given individual are encoded by approximately seven genetic loci. Published data and theoretical models agree that there is little benefit to be gained by typing and matching at a single locus. The models predict, however, that substantial benefit would be possible if multiple loci could be typed. The success of matching would be enhanced by the availability of assays that would allow typing for at least four of the loci encoding antigens that could cause GVHD in any given individual.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9244410     DOI: 10.1038/sj.bmt.1700868

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation.

Authors:  Tuna Mutis
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

2.  Does minor histocompatibility antigen HA-1 disparity affect the occurrence of graft-versus-host disease in tunisian recipients of hematopoietic stem cells?

Authors:  Mohamed Hichem Sellami; Lamia Torjemane; Alejandro Espadas de Arias; Houda Kaabi; Saloua Ladeb; Francesca Poli; Tarek Ben Othmane; Slama Hmida
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

3.  The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing.

Authors:  A G Brickner; E H Warren; J A Caldwell; Y Akatsuka; T N Golovina; A L Zarling; J Shabanowitz; L C Eisenlohr; D F Hunt; V H Engelhard; S R Riddell
Journal:  J Exp Med       Date:  2001-01-15       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.